Brief: Chemours FY Adjusted EPS USD 1.21 Vs. IBES Estimate USD 1.22
18/02/2025 11:00
Feb 18 (Reuters) - Chemours FY adjusted EBITDA USD 786 million vs. IBES estimate USD 772.8 million. * FY adjusted net income USD 182 million vs. IBES estimate USD 181.8 million * FY sales USD 5,800 million vs. IBES estimate USD 5,759 million
Recent news on The Chemours
See all newsUS RESEARCH ROUNDUP-Essex Property Trust, Qualys, Vulcan Materials
3M, DuPont must face Connecticut firefighters' lawsuit over 'forever chemicals'
Chemours, DuPont, Corteva settle North Carolina 'forever chemicals' claims for $455 million
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
New Jersey's $2.5 billion 'forever chemicals' settlements with DuPont, 3M, others win court approval